Pharmaceutical firm Mylan is dramatically expanding a nationwide recall of some blood pressure medications after detecting trace amounts of a chemical linked to cancer. The recalled products all ...
After weeks of controversy, the Centers for Medicare and Medicaid Services formally blamed Mylan Pharmaceuticals for misclassifying EpiPen with the Medicaid Drug Rebate Program. Under the program, ...
The CAFC also affirmed the district court’s ruling that Actelion failed to prove infringement by an equivalent, according to ...
Mylan CEO Heather Bresch survived an ouster attempt by angry shareholders. Heather Bresch is willing to participate in a high-profile industry conference this week, but not testify before Congress — ...
Mylan NV finalized a $465 million settlement with the U.S. Justice Department. The settlement resolves claims the pharmaceutical company overcharged the government for its EpiPen emergency allergy ...
Source: Teva Pharmaceutical via Facebook. What: Shares of Mylan, a branded-drug developer that is alsoa large player in the generic drug market, surged by 22% in April, according to data from S&P ...
Mylan has spent more than $460 million buying Novartis cystic fibrosis products. Now, it wants the plant that makes them. Mylan took an option on a Novartis plant in San Carlos, California, when it ...
Pfizer shareholders would own 57% of the new company and Mylan's shareholders would get 43%. The combined company, which will sell Mylan's EpiPen and Pfizer's Viagra, will be domiciled in the U.S. The ...
While Bob Hugin at Celgene was taking a pay cut with his move to executive chairman, Mylan’s Robert Coury most decidedly did not. In fact, Coury’s compensation skyrocketed. To $97 million. Coury’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results